Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer

Advances in Experimental Medicine and Biology

Volumn 772, Issue , 2014, Pages 189-204

  Taiakina, Daria ^a   Pra, Alan Dal ^a   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Aneuploidy; DNA repair; Genomic instability; Hypoxia; Mutator phenotype; Predictive assays; Prognosis; Prostate cancer; Radiotherapy

Indexed keywords

DNA; TUMOR SUPPRESSOR PROTEIN;

ANEUPLOIDY; CANCER GROWTH; CANCER PROGNOSIS; CELL HYPOXIA; CONFERENCE PAPER; DNA DAMAGE; DNA END JOINING REPAIR; DOWN REGULATION; EXCISION REPAIR; GENE AMPLIFICATION; GENE FUNCTION; GENOMIC INSTABILITY; HUMAN; HYPOXIA; KU70 GENE; MOLECULAR MECHANICS; NBS1 GENE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RAD51 GENE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; XRCC2 GENE;

CELL HYPOXIA; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84934444878     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5915-6_9     Document Type: Conference Paper

References (78)

1. Ahn G, Brown M (2007) Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 12:3483-3501
2. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H (1999) Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161:857-863
3. Arlt MF, Durkin SG, Ragland RL, Glover TW (2006) Common fragile sites as targets for chromosome rearrangements. DNA Repair 5:1126-1135
4. Baker DJ, Jin F, Jeganathan KB, Van Deursen JM (2009) Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell 16:475-486
5. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11:7658-7663. doi: 10.1158/1078-0432. CCR-05-0460
6. Bourke E, Dodson H, Merdes A, Cuffe L, Zachos G, Walker M, Gillespie D, Morrison CG (2007) DNA damage induces Chk1-dependent centrosome amplification. EMBO Rep 8:603-609
7. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192
8. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4(6):437-447
9. Cappelli E, Townsend S, Griffin C, Thacker J (2011) Homologous recombination proteins are associated with centrosomes and are required for mitotic stability. Exp Cell Res 317:1203-1213. doi: 10.1016/j.yexcr.2011.01.021
10. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ (2006) An immunohis-tochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 65:91-99. doi: 10.1016/j.ijrobp.2005.11.044
11. Chalmers AJ, Lakshman M, Chan N, Bristow RG (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 20:274-281
12. Chan JY (2011) A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 7:1122-1144
13. Chan N, Bristow RG (2010) "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 16:4553-4560
14. Chan N, Milosevic M, Bristow RG (2007) Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (London, England) 3:329-341
15. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG (2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68:605-614
16. Chan N, Pires IM, Bencokova Z et al (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70:8045-8054
17. Coquelle A, Toledo F, Stern S, Bieth A, Dabatisse M (1998) A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2:259-265
18. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM (2009) MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 69:1221-1229
19. Di Silverio F, D'Eramo G, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A, Seccareccia F, De Vita R (1996) DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retro-pubic prostatectomy. Eur Urol 30:316-321
20. Dodson H, Bourke E, Jeffers LJ, Vagnarelli P, Sonoda E, Takeda S, Earnshaw WC, Merdes A, Morrison C (2004) Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J 23:3864-3873. doi: 10.1038/sj.emboj.7600393
21. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361:123-134
22. Geiersbach KB, Samowitz WS (2011) Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135:1269-1277
23. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR (2008) Defining "chromosomal instability". Trends Genet 24:64-69
24. Gisselsson D (2003) Chromosome instability in cancer: how, when, and why? Adv Cancer Res 87:1-29
25. Green MML, Hiley CT, Shanks JH, Bottomley IC, West CML, Cowan RA, Stratford IJ (2007) Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67:84-90. doi: 10.1016/j. ijrobp.2006.08.077
26. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 107:2201-2206
27. Helleday T, Lo J, Van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair 6:923-935
28. Hsieh P, Yamane K (2008) DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev 129:391-407
29. Hsu LC, White RL (1998) BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 95:12983-12988
30. Jeggo P, Löbrich M (2007) DNA double-strand breaks: their cellular and clinical impact? Oncogene 26:7717-7719
31. Kaelin WG (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698
32. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159-170
33. Kitao H, Takata M (2011) Fanconi anemia: a disorder defective in the DNA damage response. Int J Hematol 93:417-424
34. Ko MJ, Murata K, Hwang D-S, Parvin JD (2006) Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle. Oncogene 25:298-303
35. Krämer A, Neben K, Ho A (2002) Centrosome replication, genomic instability and cancer. Leukemia 16:767-775
36. Kuhnert VM, Kachnic L, Li L, Purschke M, Gheorghiu L, Lee R, Held KD, Willers H (2009) FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 85:523-531
37. Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG (2012) Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 125:189-199
38. Kuzminov A (2001) Single-strand interruptions in replicating chromosomes cause double-strand breaks. Proc Natl Acad Sci USA 98:8241-8246
39. Luoto K, Kumareswaran R, Bristow RG (2013) Tumor Hypoxia as a Driving Force in Genetic Instability In Press. Genome Integrity
40. Martin S, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A (2010) DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17:235-248
41. Mazzorana M, Montoya G, Mortuza GB (2011) The centrosome: a target for cancer therapy. Curr Cancer Drug Targets 11:600-612
42. McGranahan N, Burrell R, Endesfelder D, Novelli MR, Swanton C (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13:528-538
43. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG (2005) Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol J Eur Soc Ther Radiol Oncol 76:168-176
44. Meng F, Evans JW, Bhupathi D et al (2012) Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 11:740-751
45. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak M (2005) Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol 15:43-49
46. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayana L, Jensen R, Giordano F, Randall JS, Rockwell S, Glazer PM (2003) Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 23:3265-3273
47. Mills KD, Ferguson DO, Alt FW (2003) The role of DNA breaks in genomic instability and tumor-igenesis. Immunol Rev 194:77-95
48. Milosevic M, Chung P, Parker C et al (2007) Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 67:6022-6025
49. Milosevic M, Warde P, Ménard C et al (2012) Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 18:2108-2114. doi: 10.1158/1078-0432.CCR-11-2711
50. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M (2011) Overexpression of miR-210, a downstream target of HIF1α, causes cen-trosome amplification in renal carcinoma cells. J Pathol 224:280-288
51. Nakamura H, Tanimoto K, Hiyama K, Yunokawa M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E, Nishiyama M (2008) Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. Oncogene 27:4200-4209
52. Nigg EA (2002) Centrsome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2:1-11
53. Nouspikel T (2009) Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66:994-1009
54. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, and Doxsey SJ (2001) Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 61:2212-2219
55. Pollack A (2003) Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol 21:1238-1248. doi: 10.1200/JCO.2003.02.025
56. Pollack A, Zagars GK, El-Naggar AK, Gauwitz MD, Terry NHA (1994a) Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 73:1895-1903. doi: 10.1002/1097-0142(19940401)73:73.0.CO;2-0
57. Pollack A, Zagars GK, El-Naggar K, Terry NH (1994b) Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-718
58. Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe R, Giercksky K-E, Danielsen HE (2009) Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol 31:251-259. doi: 10.3233/CLO-2009-0463
59. Rai R, Dai H, Multani AS et al (2006) BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10:145-157
60. Rai R, Phadnis A, Haralkar S, Badwe R, Dai H, Li K, Lin S-Y (2008) Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 7:2225-2233
61. Rezvani HR, Mahfouf W, Ali N, Chemin C, Ged C, Kim AL, De Verneuil H, Taïeb A, Bickers DR, Mazurier F (2010) Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucl Acids Res 38:797-809
62. Ross JS, Figge H, Bui HX, Del Rosario D, Jennings T, Rifkin MD, Fisher H (1994) Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 74:2811-2818
63. Rothkamm K, Krüger I, Thompson LH, Kru I, Lo M (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. doi: 10.1128/MCB.23.16.5706
64. Saladino C, Bourke E, Conroy PC, Morrison CG (2009) Centriole separation in DNA damage-induced centrosome amplification. Environ Mol Mutagen 50:725-732. doi: 10.1002/em
65. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, Sage C, Chen BPC, Chen DJ, Agami R, Kerem B (2005) Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev 19:2715-2726
66. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148:399-408
67. Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, Coomber BL (2005) Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res 65:8134-8141
68. Shimada M, Kobayashi J, Hirayama R, Komatsu K (2010) Differential role of repair proteins, BRCA1/NBS1 and Ku70/DNA-PKcs, in radiation-induced centrosome overduplication. Cancer Sci 101:2531-2537. doi: 10.1111/j.1349-7006.2010.01702.x
69. Smith M, Fornance A (1995) Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 7:69-75
70. Song J, Cheng WS, Cupps RE, Earle JD (1992) Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 147:794-797
71. Sprong D, Janssen HL, Vens C, Begg AC (2006) Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 64:562-572
72. Thompson SL, Bakhoum SF, Compton D (2010) Mechanisms of chromosomal instability. Curr Biol 20:R285-R295
73. Thoms JW, Dal Pra A, Anborgh PH et al (2012) Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Brit J Cancer 107:840-846. doi: 10.1038/bjc.2012.345
74. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B (2012) Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys 82:e433-e439. doi: 10.1016/j.ijrobp.2011.05.037
75. Vergis R, Corbishley CM, Norman AR et al (2008) Intrinsic markers of tumour hypoxia and angio-genesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9:342-351. doi: 10.1016/S1470-2045(08)70076-7
76. Weber DC, Tille J-C, Combescure C, Egger J-F, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R (2012) The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate-and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol (London, England) 7:66. doi: 10.1186/1748-717X-7-66
77. Wilson W, Hay M (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410
78. Wirth M, Muller H, Manseck A, Muller J, Frohmuler H (1991) Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy. Eur Urol 20:248-252